Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

The partners also announced filing acceptance of U.S. Biologics License Applications ... all rights to a biosimilar candidate referencing Cimzia® (certolizumab pegol). Xbrane’s shareholders ...

Interim Report January-March 2025, is as of today, available on the Company's website, FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted ...

Three other biologics for RA that have alternative mechanisms ... In addition, UCB has recently gained approval for certolizumab pegol (Cimzia) for the treatment of RA with a dosing regimen ...

Cimzia accounted for €1.7 billion of the ... has shown superiority to Cosentyx in a head-to-head trial, other new biologics with blockbuster sales forecasts are also aiming to steal psoriasis ...

That would help ease the pain of the forthcoming patent expiries for the Belgian drugmaker's current top-selling product Cimzia (certolizumab ... Other biologics with blockbuster sales forecasts ...

Clinical remission was achieved and sustained in nearly one third of patients with severe eosinophilic asthma (SEA) receiving benralizumab for up to 2 years, with better outcomes in biologic-naive ...

The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...